POERIO, ANGELA
 Distribuzione geografica
Continente #
NA - Nord America 1.131
EU - Europa 842
AS - Asia 509
AF - Africa 74
SA - Sud America 4
Totale 2.560
Nazione #
US - Stati Uniti d'America 1.127
GB - Regno Unito 248
SE - Svezia 167
CN - Cina 144
VN - Vietnam 128
DE - Germania 95
IT - Italia 95
SG - Singapore 88
JP - Giappone 72
UA - Ucraina 64
IN - India 45
IE - Irlanda 34
TG - Togo 33
FR - Francia 32
RU - Federazione Russa 26
CI - Costa d'Avorio 20
CH - Svizzera 16
EE - Estonia 14
JO - Giordania 14
ZA - Sudafrica 14
FI - Finlandia 12
BG - Bulgaria 11
BE - Belgio 10
GR - Grecia 8
IR - Iran 6
CA - Canada 4
NL - Olanda 4
SC - Seychelles 4
BR - Brasile 3
NG - Nigeria 3
TR - Turchia 3
BD - Bangladesh 2
KR - Corea 2
PH - Filippine 2
CL - Cile 1
CZ - Repubblica Ceca 1
ES - Italia 1
HK - Hong Kong 1
ID - Indonesia 1
LB - Libano 1
LT - Lituania 1
RO - Romania 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 2.560
Città #
Southend 216
Chandler 180
Fairfield 108
Ashburn 89
Singapore 76
Woodbridge 70
Tokyo 64
Houston 61
Dong Ket 59
Wilmington 59
Seattle 57
Ann Arbor 56
Jacksonville 44
Princeton 39
Cambridge 35
Dublin 34
Lomé 33
Santa Clara 27
Boardman 25
Turin 22
Abidjan 20
Falls Church 20
Nanjing 20
Westminster 19
New York 18
Padova 18
Amman 14
Bern 14
Helsinki 12
Berlin 11
Jinan 11
Sofia 11
Brussels 10
Beijing 9
Saint Petersburg 8
Jiaxing 7
Milan 7
Nanchang 7
San Diego 7
Taizhou 7
Shenyang 6
Bremen 5
Des Moines 5
Guangzhou 5
Hangzhou 5
Hebei 5
Medford 5
Pune 5
Tianjin 5
Changsha 4
Chiyoda-ku 4
Dearborn 4
Florence 4
Mahé 4
Munich 4
Mülheim 4
Washington 4
Abeokuta 3
Falkenstein 3
Haikou 3
Hamamatsu 3
Istanbul 3
San Venanzo 3
Verona 3
Zhengzhou 3
Bengaluru 2
Bologna 2
Cardito 2
Chicago 2
Dhaka 2
Groningen 2
Harbin 2
Kashan 2
Kunming 2
Mountain View 2
Ningbo 2
Norwalk 2
Redwood City 2
Riolo Terme 2
Rome 2
Shanghai 2
São Paulo 2
Toronto 2
Wuhan 2
Andover 1
Anyang 1
Ardabil 1
Athens 1
Baoding 1
Bratislava 1
Buk-gu 1
Cesenatico 1
Chengdu 1
Cislago 1
Davao City 1
Dongguan 1
Fremont 1
Gloucester 1
Grafing 1
Hefei 1
Totale 1.760
Nome #
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 220
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 218
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 204
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 188
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 175
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 168
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 162
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 133
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 130
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 116
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 115
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 114
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 113
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 109
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 104
null 85
null 77
null 57
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis 52
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome 48
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 39
Totale 2.627
Categoria #
all - tutte 6.031
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.031


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020302 0 0 0 0 0 0 70 69 69 38 15 41
2020/2021346 57 27 5 10 9 12 1 24 38 14 20 129
2021/2022444 51 6 34 46 36 28 9 44 12 29 78 71
2022/2023587 72 116 31 70 36 45 14 24 94 14 50 21
2023/2024211 5 21 5 18 12 90 23 15 2 3 12 5
2024/2025233 13 56 32 36 58 38 0 0 0 0 0 0
Totale 2.627